HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GI 5005

based on HCV NS3-core fusion protein

Also Known As:

GI-5005; GI5005

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Synthetic Vaccines: 1073
      - GI 5005: 2
Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Synthetic Vaccines: 1073
      - GI 5005: 2
Biological Factors: 2472
- Antigens: 143924
  - Synthetic Vaccines: 1073
    - GI 5005: 2

Experts

1.	Baumert, Thomas F: 1 article (08/2009)
2.	Habersetzer, Francois: 1 article (08/2009)
3.	Stoll-Keller, Francoise: 1 article (08/2009)
4.	Apelian, David: 1 article (02/2007)
5.	Bellgrau, Don: 1 article (02/2007)
6.	Duke, Richard C: 1 article (02/2007)
7.	Fiolkoski, Valerie: 1 article (02/2007)
8.	Franzusoff, Alex: 1 article (02/2007)
9.	Haller, Aurelia A: 1 article (02/2007)
10.	Kemmler, Charles: 1 article (02/2007)

Related Diseases

1.	Neoplasms (Cancer) 02/09/2007 - "Prophylactic as well as therapeutic administration of GI-5005 in mice led to eradication of tumor cells expressing HCV NS3 protein. "
2.	Infections 08/01/2009 - "In a phase Ib clinical trial, GI-5005 monotherapy was well tolerated and displayed efficacy in patients with chronic HCV infection. " 08/01/2009 - "GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection." 08/01/2009 - "The immunotherapeutic vaccine GI-5005, being developed by GlobeImmune Inc, is a Tarmogen (targeted molecular immunogen) consisting of recombinant Saccharomyces cerevisiae yeast expressing an HCV NS3-core fusion protein designed to elicit antigen-specific host CD4+ and CD8+ T-cell responses for the treatment of chronic HCV infection. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Vaccines
3.	Antigens